7,15-diazadispiro<5,1,5,3>hexadecane | 21430-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7,15-diazadispiro<5,1,5,3>hexadecane
• 英文别名: 7,15-Diazadispiro<5.1.5.3>hexadecan；7,15-diaza-dispiro[5.1.5.3]hexadecane；7,15-Diazadispiro[5.1.5.3]hexadecane；7,15-diazadispiro[5.1.58.36]hexadecane
• CAS: 21430-14-8
• 化学式: C₁₄H₂₆N₂
• 分子量: 222.374
• InChiKey: ZOSPIRSWAQIPSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7,15-diazadispiro<5,1,5,3>hexadecane 以71%的产率得到
  参考文献：
  名称：

  EGG H., MONATSH. CHEM. , 1975, 106, NO 5, 1175-1183

  摘要：

  DOI：
• 作为产物：
  描述：

  7,15-Diaza-dispiro<5,1;5,3>hexadecan-14,16-dion 在 lithium aluminium tetrahydride 作用下， 生成 7,15-diazadispiro<5,1,5,3>hexadecane
  参考文献：
  名称：

  Kaliska, Viera; Toma, Stefan; Lesko, Jan, Collection of Czechoslovak Chemical Communications, 1987, vol. 52, # 9, p. 2266 - 2273

  摘要：

  DOI：

文献信息

• Ultrasound effect on the synthesis of 4-alkyl-(aryl)aminobenzaldehydes
  作者：Peter Magdolen、Mária Mečiarová、Štefan Toma

  DOI：10.1016/s0040-4020(01)00403-3

  日期：2001.5

  The sonochemical nucleophilic aromatic substitutions on 4-fluorobenzaldehyde with different azacycloalkanes and azoles have been studied. A beneficial ultrasound effect was observed, reactions were clean and high yields of the products were isolated after 15 min sonication.

  已经研究了在4-氟苯甲醛上用不同的氮杂环烷烃和唑进行声化学亲核芳族取代。超声处理15分钟后，观察到有益的超声效果，反应干净，分离出高收率的产品。
• Acylated derivatives of substituted piperazines and polymeric
  申请人：Ciba-Geigy Corporation

  公开号：US04007156A1

  公开（公告）日：1977-02-08

  Acylated derivatives of substituted piperazines are stabilizers for synthetic polymeric materials normally subject to deterioration caused by ultraviolet light. The compounds are prepared by the acylation reaction between a substituted piperazine and a mono or di-acid halide, ester or isocyanate. Polymeric compositions containing these stabilizers may also contain a hindered phenolic compound. A typical embodiment is 15-stearoyl-7,15-diazadispiro[5,1,5,3]hexadecane.

  取代哌嗪的酰化衍生物是用于合成聚合材料的稳定剂，这些材料通常会因紫外线而退化。该化合物是通过取代哌嗪和单酸或双酸卤化物、酯或异氰酸酯之间的酰化反应制备而成。含有这些稳定剂的聚合物组合物也可以包含一种受阻酚化合物。一个典型的实施例是15-硬脂酰基-7,15-二氮杂二螺[5,1,5,3]十六烷。
• Substituted piperazines and polymeric compositions stabilized thereby
  申请人：Ciba-Geigy Corporation

  公开号：US04007157A1

  公开（公告）日：1977-02-08

  Substituted piperazines are stabilizers for synthetic polymeric materials normally subject to deterioration caused by ultraviolet light. The compounds are prepared by the alkylation reaction between a substituted piperazine dione and an organic halide followed by reduction with lithium aluminum hydride. Polymeric compsitions containing these stabilizers may also contain a hindered phenolic compound. A typical embodiment is 15,15'-dodecamethylene-bis(7,15-diazadispiro[5,1,5,3]hexadecane).

  取代哌嗪是合成聚合材料的稳定剂，通常受紫外线破坏。这些化合物通过取代哌嗪二酮和有机卤素之间的烷基化反应制备，并使用锂铝氢化物还原。包含这些稳定剂的聚合物组合物也可以包含阻碍酚化合物。一个典型的实施例是15,15'-十二亚甲基双(7,15-二氮杂二螺[5,1,5,3]十六烷)。
• NITROXIDES FOR LITHIUM-ION BATTERIES
  申请人：Hintermann Tobias

  公开号：US20100143805A1

  公开（公告）日：2010-06-10

  This invention relates to overcharge protection and molecular redox shuttles in rechargeable lithium-ion cells. For this, specific nitroxyls or oxoammonium salts are used in the electrolyte. This invention also relates to a method of producing such lithium-ion cells and to a method of recharging such lithium-ion cells. This invention also pertains to some nitroxyls compounds and oxoammonium salts.

  本发明涉及可充电锂离子电池中的过充保护和分子氧化还原穿梭体。为此，在电解液中使用特定的亚硝基或氧化铵盐。本发明还涉及一种生产此类锂离子电池的方法以及一种充电此类锂离子电池的方法。本发明还涉及一些亚硝基化合物和氧化铵盐。
• Piperazine Imidazo[1,5-<i>a</i>]quinoxaline Ureas as High-Affinity GABA_A Ligands of Dual Functionality
  作者：E. Jon Jacobsen、Lindsay S. Stelzer、Ruth E. TenBrink、Kenneth L. Belonga、Donald B. Carter、Haesook K. Im、Wha Bin Im、Vimala H. Sethy、Andy H. Tang、Philip F. VonVoigtlander、James D. Petke、Wei-Zhu Zhong、John W. Mickelson

  DOI：10.1021/jm9801307

  日期：1999.4.1

  A series of imidazo[1,5-alpha]quinoxaline piperazine ureas appended with a tert-butyl ester side chain at the 3-position was developed. Analogues within this series have high affinity for the gamma-aminobutyric acid A (GABA(A))/benzodiazepine receptor complex with efficacies ranging from inverse agonists to full agonists. Many analogues were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Uniquely, a number of these analogues were found to have a bell-shaped dose-response profile in the alpha(1)beta(2)gamma(2) subtype as determined by whole cell patch-clamp technique, where in vitro efficacy was found to decrease with increasing drug concentration. Many of the compounds from this series were effective in antagonizing metrazole-induced seizures, consistent with anticonvulsant and possibly anxiolytic activity. Additionally, several analogues were also effective in lowering cGMP levels (to control values) after applied stress, also consistent with anxiolytic-like properties. The most effective compounds in these screens were also active in animal models of anxiety such as the Vogel and Geller assays. The use of the piperazine substituent allowed for excellent drug levels and a long duration of action in the central nervous system for many of the quinoxalines, as determined by ex vivo assay. Pharmacokinetic analysis of several compounds indicated excellent oral bioavailability and a reasonable half-life in rats. From this series emerged two partial agonists (55, 91) which had good activity in anxiolytic models, acceptable pharmacokinetics, and minimal benzodiazepine-type side effects.